Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-2.64% $3.69
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 277.89 mill |
EPS: | -0.0700 |
P/E: | -52.71 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 75.31 mill |
Avg Daily Volume: | 0.297 mill |
RATING 2024-04-19 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Buy | |
P/E: | Strong Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -52.71 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-8.97x |
Company: PE -52.71 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-3.40 (-192.16%) $-7.09 |
Date: 2024-04-20 |
Expected Trading Range (DAY) |
---|
$ 3.33 - 4.05 ( +/- 9.67%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-22 | Gerber Brianna | Buy | 213 886 | Employee Stock Options (right to buy) |
2024-02-22 | Fried Robert N | Buy | 399 568 | Employee Stock Options (right to buy) |
2023-12-01 | Gerber Brianna | Buy | 5 000 | Common Stock |
2023-09-06 | Champion River Ventures Ltd | Buy | 3 467 778 | Common Stock |
2023-08-12 | Gerber Brianna | Sell | 22 436 | Restricted Stock Unit |
INSIDER POWER |
---|
97.85 |
Last 91 transactions |
Buy: 8 148 779 | Sell: 1 648 914 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.69 (-2.64% ) |
Volume | 0.308 mill |
Avg. Vol. | 0.297 mill |
% of Avg. Vol | 103.56 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.